Agilent Technologies 2100 Bioanalyzer G2939A Lab Analyzing Equipment
Agilent Technologies
Details
-
CategoryAnalytical
-
Dimension17.0in x 7.0in x 12.0in
-
SerialDE54107295
-
Shipping TypeFedEx Ground
-
ManufacturingDoes Not Apply
-
Voltage / Hertz100-240v / 50Hz/60Hz
Description
The Agilent Technologies 2100 Bioanalyzer G2939A is a compact lab equipment designed to perform detailed bioanalysis efficiently. Manufactured in Germany, this model is recognized for its precision and reliability in analyzing nucleic acids and proteins. It operates on a voltage range of 100-240v with a frequency of 50Hz/60Hz, making it versatile for various lab settings worldwide. Although this unit is classified as 'Good' condition with some cosmetic blemishes due to regular use, it powers on and performs basic functionality tests. It does not include power/data cables, computer, user manuals, or software. Ideal for laboratories focusing on genomics and proteomics, this bioanalyzer offers essential insights into molecular structures and functions. Computer and software are not included.
Technician comment
Has slight cosmetic blemishes from regular use. See photos for further details
Key Features
- Compact lab analyzing equipment
- Suitable for nucleic acid and protein analysis
- Operates on 100-240v and 50Hz/60Hz
- Origin: Germany
- Classified as 'Good' condition
Specifications
- Brand: Agilent Technologies
- Model: 2100 Bioanalyzer G2939A
- Condition: Good
- Power Supply: 100-240v, 50Hz/60Hz
- Country of Origin: Germany
- Use: Nucleic acids and protein analysis
- Dimensions (Actual): 17.0 in x 7.0 in x 12.0 in
- Weight: 20 lb (approx. 9.07 kg)
Weight
Imperial: 24.0 Pounds
Metric: 10.89 Kilograms
Shipping Dimensions
Imperial: 20.4 lb x 8.4 lb x 14.4 lb
Metric: 51.82 cm x 21.34 cm x 36.58 cm
Harmonized Code
9027.80.25
Harmonized Code Details
9027.80.25 - Instruments and apparatus for physical or chemical analysis. The Agilent 2100 Bioanalyzer is used for analyzing biomolecules which aligns with this classification.
Comments 0
There are currently no public comments.